Luna AI

Ask Luna AI about markets, a ticker or your clients without leaving this page.

Opening the research desk…

Vertex Pharmaceuticals Incorporated (VRTX) stock price, chart and research

Vertex Pharmaceuticals Incorporated (VRTX) last traded at $537.79 at the close on November 16, 2026, down $0.81 (0.15%) on the day.

About Vertex Pharmaceuticals Incorporated

Sector: Healthcare; industry: Biotechnology; headquarters: United States; CEO: Dr. Reshma Kewalramani FASN, M.D.; 6,400 employees; listed since 1991-07-24.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small…

Financials

Revenue over the last 12 months was $12.95 billion, net income $3.98 billion, a profit margin of 30.7%. Revenue grew 10.5% from a year earlier.

Institutional owners of VRTX (13F)

Tracked managers holding VRTX in 13F filings for the quarter ending 2026-09-30:

ETFs that hold VRTX

Research VRTX with LunaTerminal

Market data via Fear & Greed (feargreedflow.com); 13F holdings from SEC filings. Market data can be delayed; check dates before relying on a figure. Answers are research, not financial advice.

Welcome back

Sign in to your research desk.

or

New here?

Portfolio report

Create an agent

Never include secrets in agent instructions.